FDA Meetings With Biosimilar Sponsors Aim To Make 351(k) Pathway OK
This article was originally published in The Pink Sheet Daily
Executive Summary
Short public meeting on the biosimilar user fee agreement suggests the proof will be in the scheduling.
You may also be interested in...
FDA Office That Guided PDUFA V Gets New Name Highlighting Its Strategic Role
Center for Drug Evaluation and Research’s Office of Planning and Informatics has been renamed the Office of Strategic Programs and is playing a major role in implementing FDA’s patient-focused drug development initiative.
On The Trail Of Biosimilar Disclosure Scofflaws: FTC To Watch For Anti-Competitive Issues
As FDA prepares for another public hearing on the pathway, FTC says the rules requiring biosimilar applicants to share information with their reference product competitors could lead to anti-competitive issues and may be an ongoing concern.
After Pirfenidone: Broad Competition To Bring First Therapy For Underlying Cause Of IPF To Market
In the latest in “The Pink Sheet”’s market snapshot series, InterMune continues to work on getting pirfenidone approved in the U.S., while several companies are developing next-stage therapies for IPF.